Reproductive and Genetic Health (RGH) Portfolio: Tony Gordon | Illumina Video

3 March 2015

Tony Gordon, Genesis Genomics Managing Director (US) and Lab Director (UK) discusses how the Illumina portfolio empowers reproductive health labs with its ability to run both pre-and postnatal tests on the same Illumina equipment. Learn more about how next-generation sequencing (NGS) is advancing reproductive genetic health. http://www.illumina.com/clinical/reproductive-genetic-health.html?sciid=2014243IBN1

Share this article on    
    
For Research Use Only

Not for use in diagnostic procedures (except as specifically noted).

Innovative technologies

At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.

All trademarks are the property of Illumina, Inc. or their respective owners.
For specific trademark information, see emea.illumina.com/company/legal.html.

© 2024 Illumina, Inc. All rights reserved.